BIOCRYST PHARMACEUTICALS INC (BCRX) Fundamental Analysis & Valuation

NASDAQ:BCRX • US09058V1035

Current stock price

9.01 USD
+0.43 (+5.01%)
At close:
9 USD
-0.01 (-0.11%)
After Hours:

This BCRX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

5

1. BCRX Profitability Analysis

1.1 Basic Checks

  • In the past year BCRX was profitable.
  • BCRX had a positive operating cash flow in the past year.
  • BCRX had negative earnings in 4 of the past 5 years.
  • BCRX had negative operating cash flow in 4 of the past 5 years.
BCRX Yearly Net Income VS EBIT VS OCF VS FCFBCRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M -200M 300M

1.2 Ratios

  • With an excellent Return On Assets value of 51.32%, BCRX belongs to the best of the industry, outperforming 99.03% of the companies in the same industry.
  • BCRX has a better Return On Invested Capital (84.69%) than 99.81% of its industry peers.
Industry RankSector Rank
ROA 51.32%
ROE N/A
ROIC 84.69%
ROA(3y)-3.54%
ROA(5y)-17.37%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BCRX Yearly ROA, ROE, ROICBCRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K

1.3 Margins

  • BCRX has a Profit Margin of 30.16%. This is amongst the best in the industry. BCRX outperforms 94.77% of its industry peers.
  • The Operating Margin of BCRX (38.98%) is better than 97.29% of its industry peers.
  • BCRX has a better Gross Margin (97.82%) than 97.09% of its industry peers.
  • In the last couple of years the Gross Margin of BCRX has grown nicely.
Industry RankSector Rank
OM 38.98%
PM (TTM) 30.16%
GM 97.82%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.09%
GM growth 5Y1.58%
BCRX Yearly Profit, Operating, Gross MarginsBCRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600 -800 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. BCRX Health Analysis

2.1 Basic Checks

  • BCRX has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • Compared to 1 year ago, BCRX has more shares outstanding
  • Compared to 5 years ago, BCRX has more shares outstanding
  • BCRX has a better debt/assets ratio than last year.
BCRX Yearly Shares OutstandingBCRX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M
BCRX Yearly Total Debt VS Total AssetsBCRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.2 Solvency

  • An Altman-Z score of 2.31 indicates that BCRX is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • The Altman-Z score of BCRX (2.31) is better than 65.89% of its industry peers.
  • BCRX has a debt to FCF ratio of 1.36. This is a very positive value and a sign of high solvency as it would only need 1.36 years to pay back of all of its debts.
  • BCRX has a better Debt to FCF ratio (1.36) than 93.99% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 1.36
Altman-Z 2.31
ROIC/WACC9.43
WACC8.98%
BCRX Yearly LT Debt VS Equity VS FCFBCRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M -400M 600M 800M

2.3 Liquidity

  • A Current Ratio of 2.06 indicates that BCRX has no problem at all paying its short term obligations.
  • BCRX has a Current ratio of 2.06. This is in the lower half of the industry: BCRX underperforms 77.13% of its industry peers.
  • BCRX has a Quick Ratio of 2.03. This indicates that BCRX is financially healthy and has no problem in meeting its short term obligations.
  • BCRX has a Quick ratio of 2.03. This is in the lower half of the industry: BCRX underperforms 75.19% of its industry peers.
Industry RankSector Rank
Current Ratio 2.06
Quick Ratio 2.03
BCRX Yearly Current Assets VS Current LiabilitesBCRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. BCRX Growth Analysis

3.1 Past

  • BCRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 125.58%, which is quite impressive.
  • The Revenue has grown by 94.10% in the past year. This is a very strong growth!
  • BCRX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 117.92% yearly.
EPS 1Y (TTM)125.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%107.69%
Revenue 1Y (TTM)94.1%
Revenue growth 3Y47.83%
Revenue growth 5Y117.92%
Sales Q2Q%23.6%

3.2 Future

  • BCRX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 87.77% yearly.
  • The Revenue is expected to grow by 15.98% on average over the next years. This is quite good.
EPS Next Y172.89%
EPS Next 2Y113.78%
EPS Next 3Y62.18%
EPS Next 5Y87.77%
Revenue Next Year5.3%
Revenue Next 2Y8.87%
Revenue Next 3Y12.29%
Revenue Next 5Y15.98%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
BCRX Yearly Revenue VS EstimatesBCRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B
BCRX Yearly EPS VS EstimatesBCRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 1 -1 2 3 4

More info and screens

Find the best growth stocksShow best growing peers

6

4. BCRX Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 81.91 indicates a quite expensive valuation of BCRX.
  • 89.53% of the companies in the same industry are more expensive than BCRX, based on the Price/Earnings ratio.
  • Compared to an average S&P500 Price/Earnings ratio of 27.79, BCRX is valued quite expensively.
  • Based on the Price/Forward Earnings ratio of 30.02, the valuation of BCRX can be described as expensive.
  • 93.02% of the companies in the same industry are more expensive than BCRX, based on the Price/Forward Earnings ratio.
  • The average S&P500 Price/Forward Earnings ratio is at 38.88. BCRX is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 81.91
Fwd PE 30.02
BCRX Price Earnings VS Forward Price EarningsBCRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, BCRX is valued cheaper than 97.48% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, BCRX is valued cheaply inside the industry as 99.22% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 6.55
EV/EBITDA 6.31
BCRX Per share dataBCRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

  • BCRX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • BCRX's earnings are expected to grow with 62.18% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.47
PEG (5Y)N/A
EPS Next 2Y113.78%
EPS Next 3Y62.18%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BCRX Dividend Analysis

5.1 Amount

  • No dividends for BCRX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BCRX Fundamentals: All Metrics, Ratios and Statistics

BIOCRYST PHARMACEUTICALS INC

NASDAQ:BCRX (4/22/2026, 7:06:01 PM)

After market: 9 -0.01 (-0.11%)

9.01

+0.43 (+5.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26
Earnings (Next)05-06
Inst Owners83.64%
Inst Owner Change2.36%
Ins Owners0.79%
Ins Owner Change13.11%
Market Cap2.26B
Revenue(TTM)874.84M
Net Income(TTM)263.86M
Analysts85
Price Target21.73 (141.18%)
Short Float %14.74%
Short Ratio6.32
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.55%
Min EPS beat(2)-74.12%
Max EPS beat(2)67.02%
EPS beat(4)3
Avg EPS beat(4)68.25%
Min EPS beat(4)-74.12%
Max EPS beat(4)180.11%
EPS beat(8)5
Avg EPS beat(8)28.77%
EPS beat(12)7
Avg EPS beat(12)20.24%
EPS beat(16)9
Avg EPS beat(16)9.17%
Revenue beat(2)1
Avg Revenue beat(2)1.2%
Min Revenue beat(2)-4.11%
Max Revenue beat(2)6.52%
Revenue beat(4)3
Avg Revenue beat(4)5.46%
Min Revenue beat(4)-4.11%
Max Revenue beat(4)12.47%
Revenue beat(8)6
Avg Revenue beat(8)4.77%
Revenue beat(12)7
Avg Revenue beat(12)2.73%
Revenue beat(16)8
Avg Revenue beat(16)1.92%
PT rev (1m)0.47%
PT rev (3m)3.9%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-29.86%
EPS NY rev (1m)-23.66%
EPS NY rev (3m)-3.39%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.25%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.14%
Valuation
Industry RankSector Rank
PE 81.91
Fwd PE 30.02
P/S 2.58
P/FCF 6.55
P/OCF 6.51
P/B N/A
P/tB N/A
EV/EBITDA 6.31
EPS(TTM)0.11
EY1.22%
EPS(NY)0.3
Fwd EY3.33%
FCF(TTM)1.38
FCFY15.26%
OCF(TTM)1.39
OCFY15.37%
SpS3.49
BVpS-0.48
TBVpS-0.48
PEG (NY)0.47
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA 51.32%
ROE N/A
ROCE 107.2%
ROIC 84.69%
ROICexc 621.48%
ROICexgc 621.48%
OM 38.98%
PM (TTM) 30.16%
GM 97.82%
FCFM 39.42%
ROA(3y)-3.54%
ROA(5y)-17.37%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.09%
GM growth 5Y1.58%
F-Score7
Asset Turnover1.7
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 1.36
Debt/EBITDA 1.25
Cap/Depr 177.68%
Cap/Sales 0.28%
Interest Coverage 14.37
Cash Conversion 101.46%
Profit Quality 130.71%
Current Ratio 2.06
Quick Ratio 2.03
Altman-Z 2.31
F-Score7
WACC8.98%
ROIC/WACC9.43
Cap/Depr(3y)132.96%
Cap/Depr(5y)159.81%
Cap/Sales(3y)0.4%
Cap/Sales(5y)0.64%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)125.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%107.69%
EPS Next Y172.89%
EPS Next 2Y113.78%
EPS Next 3Y62.18%
EPS Next 5Y87.77%
Revenue 1Y (TTM)94.1%
Revenue growth 3Y47.83%
Revenue growth 5Y117.92%
Sales Q2Q%23.6%
Revenue Next Year5.3%
Revenue Next 2Y8.87%
Revenue Next 3Y12.29%
Revenue Next 5Y15.98%
EBIT growth 1Y13508.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-54.98%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y748.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y767.76%
OCF growth 3YN/A
OCF growth 5YN/A

BIOCRYST PHARMACEUTICALS INC / BCRX Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for BIOCRYST PHARMACEUTICALS INC?

ChartMill assigns a fundamental rating of 6 / 10 to BCRX.


What is the valuation status for BCRX stock?

ChartMill assigns a valuation rating of 6 / 10 to BIOCRYST PHARMACEUTICALS INC (BCRX). This can be considered as Fairly Valued.


What is the profitability of BCRX stock?

BIOCRYST PHARMACEUTICALS INC (BCRX) has a profitability rating of 5 / 10.


What is the financial health of BIOCRYST PHARMACEUTICALS INC (BCRX) stock?

The financial health rating of BIOCRYST PHARMACEUTICALS INC (BCRX) is 6 / 10.